LEVEL is a privately owned California cannabis company founded in 2015 by chemist Chris Emerson, PhD. It specializes in tablets rather than flower, organizing products by strength, input material and cannabinoid formulation. The range includes LEVEL 5 and LEVEL 10, Protab, Protab+, Protab Max, Hashtab, Rosintab and hemp-derived products. State-regulated offerings appear in California, Nevada, New Jersey, New York and Pennsylvania, with market-specific doses and package configurations.
Chris and Brie Emerson
Chris Emerson is the founder, chief scientist and chief executive. His background includes a doctorate in small-molecule chemistry, a Stanford postdoctoral fellowship and U.S. Navy service as a Chinese interpreter. Brie Emerson is co-owner and chief operating officer, bringing sales and team-building experience. The founders position LEVEL at the intersection of plant chemistry and product formulation. That scientific identity does not turn the tablets into approved medicines; the company publishes the required disclaimer that products are not intended to diagnose, treat, cure or prevent disease.
LEVEL 5, LEVEL 10 and Protab
LEVEL 5 and LEVEL 10 provide lower-dose swallowable tablets in effect-oriented varieties. Protab is a higher-strength line that includes THC and non-intoxicating cannabinoid versions, with scored tablets in selected products. Protab+, Protab 50, Protab 100 and Protab Max extend the range into substantially higher per-unit amounts where state rules allow. Names such as Energy or Slumber describe formulation goals, not a guaranteed personal outcome. Milligrams per tablet and package total must be checked before use.
Products
Hashtab uses cold-water hash in a swallowable tablet, while Rosintab uses live rosin. Those inputs distinguish them from tablets formulated with other cannabis concentrates. Solventless does not mean non-intoxicating: both lines can contain meaningful THC. Product listings describe several-hour duration estimates, but individual timing depends on dose, metabolism, food and tolerance. Consumers should wait before taking more and should not apply the onset of inhaled cannabis to an oral tablet.
Minor cannabinoids and ratios
LEVEL formulates with cannabinoids including CBD, CBG, CBN, THCA and THCV in addition to delta-9 THC. A measured tablet can make a ratio easier to identify than an unlabeled portion of food, but it does not make a response predictable. Effect-oriented combinations should be assessed through the exact ingredient and cannabinoid panel. People using medications, managing health conditions or avoiding intoxication should seek qualified guidance rather than relying on a product name.
Where it operates
The company publishes California manufacturing license CDPH-10004472. Regulated tablets are produced and sold inside state cannabis systems. Hemp products follow a separate online channel and legal framework, so they should not be confused with state-licensed high-THC products. Availability differs by state; for example, a strength offered in Nevada or New York may not be present everywhere. A local retailer and sealed package provide the relevant market, manufacturer and dosage details.
Production
LEVEL maintains a test-results library with batch identifiers, including 2025 and 2026 entries. Consumers should match the code on their package rather than relying on a report for the same product name from another run. Tablets must be secured away from children and anyone who could mistake them for ordinary supplements. Adults should begin with a suitable dose, avoid driving while impaired and follow local law. @level.experience is the company’s public Instagram handle.